(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/165081 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/60* (2017.01)
A61K 9/19 (2006.01) *A61K 47/18* (2017.01)
A61K 38/27 (2006.01) *A61K 47/12* (2006.01)
A61K 47/26 (2006.01)

(21) International Application Number:
PCT/EP2020/053304

(22) International Filing Date:
10 February 2020 (10.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
19156488.9 11 February 2019 (11.02.2019) EP

(71) Applicant: **ASCENDIS PHARMA GROWTH DISORDERS A/S** [DK/DK]; Tuborg Boulevard 5, 2900 Hellerup (DK).

(72) Inventors: **SKANDS, Anja R.H.**; c/o Ascenids Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). **HERSEL, Ulrich**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE). **PINHOLT, Charlotte**; c/o Ascendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). **HEINIG, Stefan**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE).

(74) Agent: **BÜCHEL, Edwin**; Patentanwälte Isenbruck Bösl Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163 Mannheim (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2020/165081 A1

(54) Title: DRY PHARMACEUTICAL FORMULATIONS OF CNP CONJUGATES

(57) Abstract: A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety.